Guidance Presents Challenging Set Up for Biogen (BIIB) in 2022 - BMO Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Biogen (BIIB) PT Lowered to $304 at Stifel
February 3, 2022 11:12 AM ESTStifel analyst Paul Matteis lowered the price target on Biogen (NASDAQ: BIIB) to $304.00 (from $344.00) while maintaining a Buy rating following earnings.
The analyst commented, "Biogen's 4Q21 earnings call was fundamentally a non-event, as few specifics were offered on whether there's a feasible... More
Biogen (BIIB) Shares Fall as Guidance Comes In Below Consensus, Analyst Says Focus Remains on Aduhelm Coverage
February 3, 2022 10:37 AM ESTShares of Biogen (NASDAQ: BIIB) are down 3% in todays trading session after the company reported mixed results and guidance.
The biotechnology company reported EPS of $2.50, or $368.2 million, up from $2.33 per share, or $357.9 million, from the year-ago quarter. Adjusted EPS came in at $3.39, beating the FactSet consensus of $3.37.... More
